Earnings Call · Q4 FY2024·2025-02-04

Q4 24EPS +2.99%·Rev n/aQ3 24EPS 0.00%·Rev n/aQ2 24EPS +6.54%·Rev n/aQ1 24EPS +7.81%·Rev n/a⚠ consensus missing

Merck & Co., Inc. MRK

Peter Dannenbaum — Vice President, Investor Relations

Rob Davis — Chairman and Chief Executive Officer

Caroline Litchfield — Chief Financial Officer

Dr. Dean Li — President, Merck Research Laboratories

−9.1%1d on move date−9.7% vs SPY3d−11.8%5d−13.4%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more MRK calls or request research access.

More MRK calls Browse calls Request research access